OR WAIT null SECS
March 25, 2026
Video
Bhatt shares his thoughts on the recently released dyslipidemia guidelines, highlighting the return of goal-based LDL-C therapy and Lp(a) receiving a COR 1 suggestion.
March 23, 2026
New dyslipidemia guidance sharpens risk with CAC, checks lipoprotein(a), and targets LDL goals using expanded therapies for prevention.
New dyslipidemia guidance sets LDL targets for FH, urges genetic testing, and highlights evinacumab and APOC3 drugs for severe triglycerides.
Trials show most heart supplements don’t lower LDL or prevent events; learn why omega‑3s, vitamins and red yeast rice fall short of statins.
New lipid guidelines sharpen LDL goals for diabetes, HIV, CKD, cancer survivors and seniors, highlighting statins’ power and shared decisions.
New lipid guidance brings back LDL targets by risk, pairing percent reduction with absolute goals—and explains why lower is better.
New US guidance spotlights one-time lipoprotein(a) tests and ApoB targets to uncover hidden heart risk and fine-tune lipid therapy.
New guidance shows how risk enhancers and coronary calcium scores refine statin decisions, including handling incidental CAC on routine CT scans.
New ACC/AHA lipid update explains PREVENT risk equations, updated thresholds, and when to start statins or CAC scoring to prevent heart attacks.
